Counterfeiting in global pharmaceuticals sector: its consequences and management
by Derek L. Bosworth
International Journal of Intellectual Property Management (IJIPM), Vol. 3, No. 4, 2009

Abstract: This paper argues that some acts of counterfeiting as in pharmaceuticals have both an economic cost for branded producers and major social and welfare costs. The risks for the individual appear particularly high in developing countries. Branded manufacturers may experience a loss of faith amongst consumers and be forced to withdraw their pharmaceutical product from the market. The paper considers the link between parallel imports and counterfeit pharmaceuticals and also the trade in pharmaceuticals on the internet. It also investigates the links between counterfeiting and other criminal activities. Finally it examines various anti-counterfeiting strategies, including 'track and trace' technologies.

Online publication date: Wed, 08-Jul-2009

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com